Press Release

Celito Tech Inc Announces Appointment of Jeet Mahal to the Board of Directors

“We are thrilled to have Jeet Mahal join our Board of Directors, an addition that perfectly aligns with Celito Tech, Inc.’s ongoing commitment to provide cost-effective, next generation technology solutions to the life sciences sector,” said Vikas Kawatra, CEO and co-founder of Celito Tech, Inc. “Celito’s vision is to empower life science companies by allowing them to strategically harness the latest technology and data solutions on top of a foundational infrastructure supporting Identity Management, Document Management and Cybersecurity functions. Jeet’s diverse operating experiences in various biopharma companies will play a vital role in advancing our mission to transform the life sciences landscape through technology and strategic insight.”

Jeet Mahal expressed excitement about joining Celito Tech, Inc.’s Board of Directors stating, “Celito Tech has quickly become the premiere provider of advanced information technology solutions to new and existing biotech companies. I have been impressed with their deep domain expertise and knowledge of key regulatory and other requirements that are unique to our highly regulated industry. I look forward to collaborating with the talented team and contributing to the company’s next set of innovative technology solutions.”

Mr. Mahal has been in drug development at various biotechnology and pharmaceutical companies for over 30 years. He is currently the Chief Operating Officer of Jasper Therapeutics and at various points since the company’s inception has been responsible for the Finance, Business Development, Marketing, Regulatory, Quality and IT functions. Prior to joining Jasper, he was Vice President, Business Development and Vice President, Strategic Marketing at Portola Pharmaceuticals, where he led the successful execution of multiple business development partnerships for Andexxa®, Bevyxxa® and cerdulatinib. He also played a key role in the company’s equity financings, including its initial public offering and multiple royalty transactions. Earlier in his career, Mr. Mahal was Director, Business and New Product Development, at Johnson & Johnson on the Xarelto® development program. Mr. Mahal started in industry at COR Therapeutics in a variety of technical roles focused on the development of Integrilin®. Mr. Mahal holds a BA in Molecular and Cell Biology from U.C. Berkeley, a Master’s in Molecular and Cell Biology from the Illinois Institute of Technology, a Master’s in Engineering from North Carolina State University and an MBA from Duke University.

About Celito Tech, Inc.:
Celito Tech, Inc. is a prominent technology solutions company focused on the design and delivery of robust, secure, technology solutions to the life sciences sector. Celito Tech’s offerings include ground up deployment of integrated systems to support identity management, device management, secure computing environments, lifesciences tailored cybersecurity posture and specialized R&D, quality, clinical operations and regulatory systems. In addition, Celito Tech is developing proprietary next generation document management, workflow, and Artificial Intelligence solutions for the life sciences sector to allow companies to fully utilize their internal data for data-driven decision making. With over 50 current customers Celito Tech is a leading provider of next generation computing infrastructure to tomorrow’s life sciences leaders.

About Celito AI:
Celito AI is an innovative Generative AI product designed for the life sciences industry, provides ChatGPT-like interactive insights, enhancing research and decision-making. Tailored for both SaaS and enterprise clients, it seamlessly integrates with public data sources like FDA, ClinicalTrials.gov, and SEC, and connects to internal content platforms such as Box and SharePoint.
 
 
Contact Information:
Celito Tech Public Relations
PR@celitotech.com